---
title: "Cantor Fitzgerald Sticks to Its Buy Rating for HCA Healthcare (HCA)"
description: "According to TipRanks, James is a 4-star analyst with an average return of 6.1% and a 58.16% success rate. James covers the Healthcare sector, focusing on stocks such as Tenet Healthcare, Centene, and"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260173513.md"
published_at: "2025-10-07T14:05:21.000Z"
---

# Cantor Fitzgerald Sticks to Its Buy Rating for HCA Healthcare (HCA)

> According to TipRanks, James is a 4-star analyst with an average return of 6.1% and a 58.16% success rate. James covers the Healthcare sector, focusing on stocks such as Tenet Healthcare, Centene, and HCA Healthcare. Currently, the analyst consensus on HCA Healthcare is a Moderate Buy with an average price target of $408.69.

According to TipRanks, James is a 4-star analyst with an average return of 6.1% and a 58.16% success rate. James covers the Healthcare sector, focusing on stocks such as Tenet Healthcare, Centene, and HCA Healthcare.

Currently, the analyst consensus on HCA Healthcare is a Moderate Buy with an average price target of $408.69.

### Related Stocks

- [HCA.US - HCA Healthcare](https://longbridge.com/en/quote/HCA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Top HCA Healthcare Executives Cash In With Major Stock Moves | HCA Healthcare executives, including Senior VP Christopher F. Wyatt and Chief HR Officer Jennifer Berres, executed signi | [Link](https://longbridge.com/en/news/275853104.md) |
| HCA Healthcare Unusual Options Activity For February 11 | HCA Healthcare (NYSE:HCA) has seen unusual options activity, with 9 significant trades detected, indicating a bullish se | [Link](https://longbridge.com/en/news/275638091.md) |
| Jim Cramer on HCA Healthcare: “I think it’s a terrific one to buy” | Jim Cramer is bullish on HCA Healthcare (NYSE:HCA) due to its share buyback activity, which has significantly reduced it | [Link](https://longbridge.com/en/news/270408434.md) |
| Jorie AI Shares a Live Case Study on the Inevitable Future of Healthcare AI at ViVE 2026 | Jorie AI showcased its autonomous healthcare AI solutions at ViVE 2026, emphasizing the need for AI to operate effective | [Link](https://longbridge.com/en/news/275497445.md) |
| Evercore ISI Sticks to Their Buy Rating for CVS Health (CVS) | Evercore ISI analyst Elizabeth Anderson maintained a Buy rating on CVS Health (CVS) with a price target of $100.00. Ande | [Link](https://longbridge.com/en/news/275622408.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
